Lemierre's syndrome and genetic polymorphisms: A case report

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Constantin, Jean Michel ^a   Mira, Jean Paul ^b   Guerin, Renaud ^a   Cayot Constantin, Sophie ^a   Lesens, Olivier ^a   Gourdon, Florence ^a   Romaszko, Jean Pierre ^a   Linval, Philippe ^c   Laurichesse, Henri ^a   Bazin, Jean Etienne ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b Cochin Saint Vincent de Paul University Hospital ^*  (France)

^c Department of Anesthesiology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTAXIME; CILASTATIN PLUS IMIPENEM; ERYTHROMYCIN; GENTAMICIN; HYDROCORTISONE; INITIATION FACTOR 4G; METRONIDAZOLE; PENICILLIN G; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TOLL LIKE RECEPTOR 5;

ADOLESCENT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; CASE REPORT; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; DNA DETERMINATION; DRUG DOSE REGIMEN; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; INNATE IMMUNITY; LABORATORY TEST; LEMIERRE SYNDROME; NONHUMAN; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; THROMBOSIS;

ADOLESCENT; FEMALE; FUSOBACTERIUM INFECTIONS; FUSOBACTERIUM NECROPHORUM; HUMANS; PHARYNGITIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPIRATORY DISTRESS SYNDROME, ADULT; SHOCK, SEPTIC; SYNDROME; THROMBOPHLEBITIS; THROMBOPLASTIN; TOLL-LIKE RECEPTOR 5;

EID: 33747160450     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-115     Document Type: Article

References (14)

1. Lemierre A: On certain septicaemias due to anaerobic organisms. Lancet 1936, 1:701-703.
2. Hagelskjaer LH, Prag J, Malczynski J, Kristensen JH: Incidence and clinical epidemiology of necrobacillosis, including Lemierre's syndrome, in Denmark 1990-1995. Eur J Clin Microbial Infect Dis 1998, 17(8):561-565.
3. Citron DM: Update on the taxonomy and clinical aspects of the genus fusobacterium. Clin Infect Dis 2002, 35(Suppl 1):S22-7.
4. Tan ZL, Nagaraja TG, Chengappa MM: Fusobacterium necrophorum infections: virulence factors, pathogenic mechanism and control measures. Vet Res Commun 1996, 20(2):113-140.
5. Desvaux M, Khan A, Beatson SA, Scott-Tucker A, Henderson IR: Protein secretion systems in Fusobacterium nucleatum: genomic identification of Type 4 piliation and complete Type V pathways brings new insight into mechanisms of pathogenesis. Biochim Biophys Acta 2005, 1713(2):92-112.
6. Hawn TR, Verbon A, Lettinga KD, Zhao LP, Li SS, Laws RJ, Skerrett SJ, Beutler B, Schroeder L, Nachman A, Ozinsky A, Smith KD, Aderem A: A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med 2003, 198(10):1563-1572.
7. Schmid T, Miskin H, Schlesinger Y, Argaman Z, Kleid D: Respiratory failure and hypercoagulability in a toddler With Lemierre's syndrome. Pediatrics 2005, 115(5):e620-2.
8. Balta G, Altay C, Gurgey A: PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol 2002, 71(2):89-93.
9. Texereau J, Pene F, Chiche JD, Rousseau C, Mira JP: Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004, 32(5 Suppl):S313-9.
10. Segui R, Estelles A, Mira Y, Espana F, Villa P, Falco C, Vaya A, Grancha S, Ferrando F, Aznar J: PAI-1 promoter 4G/5G genotype as an additional risk factor for venous; thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 2000, 111(1):122-128.
11. Westendorp RG, Hottenga JJ, Slagboom PE: Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999, 354(9178):561-563.
12. Menges T, Hermans PW, Little SG, Langefeld T, Boning O, Engel J, Sluijter M, de Groot R, Hempelmann G: Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001, 357(9262):1096-1097.
13. Haralambous E, Hibberd ML, Hermans PW, Ninis N, Nadel S, Levin M: Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 2003, 31(12):2788-2793.
14. Ott I, Koch W, von Beckerath N, de Waha R, Malawaniec A, Mehilli J, Schomig A, Kastrati A: Tissue factor promotor polymorphism -603 A/G is associated with myocardial infarction. Atherosclerosis 2004, 177(1):189-191.